Table 4. Clinical outcome of included patients.

Variables	Patients (n = 11)
Technical success, n (%)	11 (100)
Total bilirubin, median (range), mg/dL
At admission	5.8 (2.8 – 32.1)
1 day after ID-RFA	2.4 (0.6 – 8.0)
4 weeks after ID-RFA	1.1 (0.5 – 4.7)
ID-RFA related early adverse events, n (%)
Perforation	0
Hemobilia	0
Cholangitis	0
Pancreatitis and fever	1 (9.1)
Fever only	5 (45.5)
Total follow-up duration, median (range), d	98 (30 – 207)
30-day stent patency, n (%)	11 (100)
Stent occlusion, n (%)	3 (27.3)
Mortality during follow-up period, n (%) 1	2 (18.2)

ID-RFA, intraductal radiofrequency ablation

¹Overall survival was 151 days and 191 days for each case.